Publication Name	World Journal of Gastroenterology
Manuscript ID	43226
Country	United States

Received	2018-10-30 07:48
Peer-Review Started	2018-11-01 01:15
To Make the First Decision	2018-11-29 09:28
Return for Revision	2018-12-17 07:18
Revised	2019-01-10 02:38
Second Decision	2019-01-14 09:05
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2019-01-15 01:43
Articles in Press	2019-01-15 01:43
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2019-02-13 09:38
Publish the Manuscript Online	2019-02-14 09:57

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Minireviews
Article Title	Cancer risk in primary sclerosing cholangitis: Epidemiology, prevention, and surveillance strategies
Manuscript Source	Invited Manuscript
All Author List	Brian M Fung, Keith D Lindor and James H Tabibian
Funding Agency and Grant Number
Corresponding Author	James H Tabibian, MD, PhD, Health Sciences Clinical Associate Professor, David Geffen School of Medicine at UCLA, Director of Endoscopy, Olive View-UCLA Medical Center, 14445 Olive View Drive, 2B-182,, Sylmar, CA 91342, United States. jtabibian@dhs.lacounty.gov
Key Words	Bile duct diseases; Cholangiocarcinoma; Gallbladder carcinoma; Hepatocellular carcinoma; Colorectal cancer; Chemoprotection; Inflammatory bowel disease
Core Tip	Primary sclerosing cholangitis is a rare cholestatic liver disease characterized by progressive fibroinflammatory destruction of the bile ducts. It is associated with a significantly increased risk of malignancy over the general population, with nearly 50% of deaths in patients with primary sclerosing cholangitis caused by cancer, thus necessitating robust surveillance strategies. In this article, we provide a synopsis of the epidemiology, prevention, and surveillance of cancers in patients with primary sclerosing cholangitis.
Publish Date	2019-02-14 09:57
Citation	Fung BM, Lindor KD, Tabibian JH. Cancer risk in primary sclerosing cholangitis: Epidemiology, prevention, and surveillance strategies. World J Gastroenterol 2019; 25(6): 659-671
URL	https://www.wjgnet.com/1007-9327/full/v25/i6/659.htm
DOI	https://dx.doi.org/10.3748/wjg.v25.i6.659

Full Article (PDF)	WJG-25-659.pdf
Full Article (Word)	WJG-25-659.docx
Manuscript File	43226-Review.docx
Answering Reviewers	43226-Answering reviewers.pdf
Audio Core Tip	43226-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	43226-Conflict-of-interest statement.pdf
Copyright License Agreement	43226-Copyright license agreement.pdf
Peer-review Report	43226-Peer-review(s).pdf
Scientific Misconduct Check	43226-Scientific misconduct check.pdf
Scientific Editor Work List	43226-Scientific editor work list.pdf